The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Xeljanz (tofacitinib), also known as Xeljanz XR and tofacitinib citrate, on March 6, 2026. This approval, submitted by sponsor Pfizer, specifically addresses an update to the drug's efficacy profile.
Background
Tofacitinib, marketed under the brand names Xeljanz and Xeljanz XR, is an oral medication developed by Pfizer. It is also known by its chemical name, tofacitinib citrate. This supplemental application, classified under 'Efficacy,' indicates a regulatory update concerning the drug's demonstrated effectiveness. The FDA's action on this supplemental application (NDA 213082 S-13) reflects an ongoing evaluation of tofacitinib's clinical profile.
What this means
This supplemental approval for Xeljanz (tofacitinib) signifies an official update to the drug's efficacy information. For clinicians, this means there may be new or revised data regarding how effective tofacitinib is for its approved uses, potentially impacting prescribing decisions or patient counseling. Researchers and patient advocates should consult the full updated prescribing information, which will detail the specific changes and the data supporting this efficacy update. This type of approval typically reflects new clinical data or a re-evaluation of existing data that warrants a change in the drug's official labeling.
Source
The information regarding this major supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) database. The approval for supplemental application NDA 213082 S-13 for Xeljanz (tofacitinib) was recorded on March 6, 2026, as an efficacy update. This official record is publicly accessible on accessdata.fda.gov, providing transparent regulatory information for healthcare professionals, researchers, and the public.